Publications
55
Citations
1,598
Est. group size
~19
Recurring co-author estimate
Active years
10
Publishing since 2016
Kristin L Koenig's research centers on acute myeloid leukemia (AML) and related blood cancers, particularly in older adults. Her work includes clinical trials testing new drug combinations (such as venetoclax, azacitidine, and targeted inhibitors like gilteritinib and CPX-351) and genomic/molecular studies to understand how specific mutations affect treatment outcomes in AML and myelodysplastic syndromes (MDS).
Publication output has grown substantially over the last decade, rising from occasional papers before 2020 to a sustained high output of 12-14 papers per year from 2023 through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial
Blood Cancer Journal · 2025
- V-RULES: Real-world effectiveness and safety of CPX-351 in patients with secondary acute myeloid leukemia (AML).
Journal of Clinical Oncology · 2025
- AML-976: V-RULES: Impact of Treatment Setting on CPX-351 Safety and Effectiveness in Secondary Acute Myeloid Leukemia
Clinical Lymphoma Myeloma & Leukemia · 2025
- POSTER: AML-976 V-RULES: Impact of Treatment Setting on CPX-351 Safety and Effectiveness in Secondary Acute Myeloid Leukemia
Clinical Lymphoma Myeloma & Leukemia · 2025
- Effectiveness and safety of CPX-351 in younger patients <60 years with newly diagnosed secondary Acute Myeloid Leukemia: Pooled analysis of US (V-RULES) and UK (CREST-UK) real-world studies
Blood · 2025
- <i>IDH2</i> Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
Blood · 2024
- A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years
Blood · 2024
- A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with <i>FLT3</i>-Mutated Relapsed or Refractory Acute Myeloid Leukemia
Blood · 2024
- A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 (Lacutoclax) As Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Blood · 2024
- P492: SAFETY AND EFFICACY OF LP-108 AS MONOTHERAPY AND COMBINED WITH AZACITIDINE IN PATIENTS WITH RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR ACUTE MYELOID LEUKEMIA
HemaSphere · 2023
- A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years
Blood · 2023
- Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated <i>FLT3</i> Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)
Blood · 2023
- Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial
Blood · 2023
- A Phase II Study of Clinical Efficacy of Venetoclax in Combination with Azacitidine in Patients with Therapy Related Myelodysplastic Syndrome (t-MDS)
Blood · 2023
- Supplementary Figures S1 - S10, Tables S1 - S2 from Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse
2023
- Blood×22
- Journal of Clinical Oncology×6
- Clinical Lymphoma Myeloma & Leukemia×6
- Blood Advances×2
- Cancer Discovery×1
- Bei Liu
Medicine · The Ohio State University
- Michael Ozga
Medicine · The Ohio State University
- Bhavana Bhatnagar
Medicine · The Ohio State University
- Nicole Abbott
Medicine · The Ohio State University
- Uma Borate
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile